IO Biotech, Inc. IOBT 深 滬
等待開盤 09-23 09:30:00 美东时间
1.49
-0.070
-4.49%
華盛通- 最 高1.60
- 今 開1.57
- 成交量 80.38万股
- 最 低 1.48
- 昨 收 1.56
- 總市值 9816.25万
- 52周最高 2.79
- 市盈率 靜 --
- 換手率 1.22%
- 52周最低 0.66
- 委 比 -41.13%
- 總股本 6588.09万
- 歷史最高 17.88
- 量 比 0.57
- 振 幅 7.69%
- 歷史最低 0.66
- 每 手 1
- 風險率 0.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多IO Biotech Announces Participation in Upcoming Investor Conferences
IO Biotech's senior management will present at Morgan Stanley's Global Healthcare Conference on September 9 and H.C. Wainwright's Global Investment Conference on September 10. The company's lead candidate, Cylembio, is in pivotal Phase 3 and two Phase 2 trials for advanced melanoma and solid tumors, with results expected in Q3 2025. IO Biotech is a clinical-stage biopharma company developing immune-modulatory cancer vaccines.
09-04 12:05
美股牛股 | 中概股迅雷涨26.5%；生物制药公司IO Biotech涨68.8%
IO Biotech, Inc.涨68.8%；PRECIGEN涨58.9%；Sunrun涨32.8%
08-16 09:33
IO Biotech Q2 EPS $(0.40) Misses $(0.35) Estimate
IO Biotech (NASDAQ:IOBT) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.35) by 13.64 percent. This is a 29.03 percent decrease over losses of $(0.31) per share from the
08-15 04:35
IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights
IO Biotech reported Q2 2025 results, including a Phase 3 trial of Cylembio® + KEYTRUDA® showing clinical improvement in progression-free survival (PFS) vs. KEYTRUDA alone in advanced melanoma, though statistical significance was narrowly missed. The company plans to meet with FDA this fall to discuss data. Cash ended Q2 at $28.1M, with funds from European Investment Bank expected to support operations into 2026. IO Biotech will present at the Mor...
08-14 20:05
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers IO Biotech (NASDAQ:IOBT) stock rose 52.5% to $2.76 during Monday's pre...
08-11 20:08
Market-Moving News for August 11th
MNDY: -19% | Monday.Com Q2 Adj. EPS $1.09 Beats $0.86 Estimate, Sales $299.01M Beat $293.54M Estimate IOBT: 66% | Reported Sunday, IO Biotech To Reveal Topline Phase 3 Results For Cylembio Plus KEYTRUDA In
08-11 19:25
IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed
IO Biotech announced topline results from a pivotal Phase 3 trial of its investigational cancer vaccine Cylembio in combination with pembrolizumab for the treatment of advanced melanoma. The trial showed an improvement in progression-free survival (PFS) for patients treated with Cylembio plus pembrolizumab compared to pembrolizumab alone (median PFS 19.4 months vs. 11.0 months), though statistical significance on the primary endpoint was narrowly...
08-11 12:00
IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma
IO Biotech will hold a conference call on August 11, 2025, to discuss Phase 3 trial results of its cancer vaccine, Cylembio, in treating advanced melanoma. The company, developing immune-modulatory vaccines, has seen its candidate granted Breakthrough Therapy Designation by the FDA. The call will provide insight into the pivotal trial comparing Cylembio with pembrolizumab alone.
08-10 12:00
IO Biotech Elects New Director at Annual Meeting
The latest update is out from IO Biotech ( ($IOBT) ). On June 5, 2025, IO Biote...
06-10 05:17
IO Biotech Files For For Resale Of Up To 5,623,664 Shares By Selling Stockholders
-SEC Filing
05-24 04:09
